Patents by Inventor Nilesh Wagh

Nilesh Wagh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
    Patent number: 11541133
    Abstract: A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 3, 2023
    Assignees: RADIOMEDIXINC., ORANO MED
    Inventors: Izabela Tworowska, Nilesh Wagh, Ebrahim S. Delpassand, Federico Rojas-Quijano, Paul Jurek, Garry E. Kiefer, Tania A. Stallons, Amal Saidi, Julien Torgue
  • TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES
    Publication number: 20190336623
    Abstract: A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.
    Type: Application
    Filed: January 12, 2018
    Publication date: November 7, 2019
    Inventors: Izabela TWOROWSKA, Nilesh WAGH, Ebrahim S. DELPASSAND, Federico ROJAS-QUIJANO, Paul JUREK, Garry E. KIEFER, Tania A. STALLONS, Amal SAIDI, Julien TORGUE
  • Anti inflammatory compounds
    Patent number: 8236843
    Abstract: Biphenyl compounds of Formula (I) and Formula (II), and their pharmaceutically acceptable salts or solvates or prodrugs, their pharmaceutical compositions, their use and process of preparation are provided. Compounds of Formula (I) and Formula (II) are disclosed to exhibit anti-inflammatory properties.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: August 7, 2012
    Assignee: Elder Pharmaceuticals Ltd.
    Inventors: Rajiv R. Sakhardande, Vithal Kulkarni, Nilesh Wagh, Manmohan Nimbalkar, Suhas M. Nadkarni
  • ANTI INFLAMMATORY COMPOUNDS
    Publication number: 20110263543
    Abstract: Biphenyl compounds of Formula (I) and Formula (II), and their pharmaceutically acceptable salts or solvates or prodrugs, their pharmaceutical compositions, their use and process of preparation are provided. Compounds of Formula (I) and Formula (II) are disclosed to exhibit anti-inflammatory properties.
    Type: Application
    Filed: August 24, 2009
    Publication date: October 27, 2011
    Inventors: Rajiv R. Sakhardande, Vithal Kulkarni, Nilesh Wagh, Manmohan Nimbalkar, Suhas M. Nadkarni